ImmunoPrecise Antibodies股票討論區

$ImmunoPrecise Antibodies(IPA.US)$
NEWS
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 /ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TMPlatform. LENSai, which is run by the company's subsidiary, BioStrand, provides a ...

$ImmunoPrecise Antibodies(IPA.US)$
NEWS
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments

$ImmunoPrecise Antibodies(IPA.US)$ NEWS
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand And InterSystems Announce A Collaboration For AI-Driven Healthcare Applications

$ImmunoPrecise Antibodies(IPA.US)$ NEWS
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga 'This Collaboration Integrates the New Vector Search Capability of the InterSystems IRIS Data Platform With IPA's Subsidiary BioStrand's LENS Platform for AI-driven Applications in Healthcare'

$ImmunoPrecise Antibodies(IPA.US)$ piece of garbage stock.

$ImmunoPrecise Antibodies(IPA.US)$ Press Release: IPA Acquires the Carterra LSA(R) Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
Dow Jones· 4 mins ago

$ImmunoPrecise Antibodies(IPA.US)$ Financial Performance:
ImmunoPrecise reported a Q3 2024 revenue of $6.2 million, a 20.3% increase year-over-year.
Year-to-date revenue reached $18.1 million, showing a 20% rise from fiscal 2023.
The company reduced its net loss to $2.9 million or $0.11 per share from the previous year's loss of $4.7 million, or $0.19 per share.
Cash balance at the end of Q3 2024 was $6.2 million, compared to $8.3 million in the previous year.
R&D expenses were app...